Organisation paid for research Program year 2025 Source: CMS Open Payments

VitreoRetinal Surgery, PLLC

Neither a doctor nor a teaching hospital

Research payments

$464,079

188 payments

Through program year 2025, VitreoRetinal Surgery, PLLC is reported as receiving $464,079 in research payments, across 188 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$109,928	58
2024	Research	$354,152	130

Breakdown

Who paid Research payments · program years 2024–2025

Apellis Pharmaceuticals, Inc. $452,129 184 payments
Astellas Pharma Global Development $11,950 4 payments

Studies the money was for Research payments · program years 2024–2025

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration $349,784 149 payments
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD $102,346 35 payments
A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration $11,950 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.